CHRS - Rasio rega marang prakiraan pendapatan Coherus BioSciences, Inc.

Coherus (CHRS) - logo korporat

Intense competition in the biosimilars sector is forcing Coherus Biosciences (CHRS) to offer significant discounts to insurers, which increases operating expenses. The projected P/S trend visualizes this balance, while the 1.50 metric confirms the current valuation level. Meanwhile, the company maintains premium pricing for innovative drugs, leveraging high macro-resilience and stable demand in oncology.

Coherus BioSciences Inc. - Prakiraan rega marang pendapatan CHRS (periode 04.07.2022 - 16.11.2026)

Rincian metrik komprehensif lan analitis Coherus BioSciences (CHRS)

Analisis umum perusahaan:Coherus BioSciences, Inc. CHRS
Produk sing diprodhuksi coherus.com

Using forward multiples minimizes the impact of market volatility, allowing for a valuation of Coherus Biosciences (CHRS) based on expected biosimilar and oncology drug sales. By analyzing the forward P/S ratio dynamics on the GURU.Markets platform, an investor can see the relationship between current market capitalization and future revenue, which helps determine the extent to which the market has priced in the expansion potential of the company's pharmaceutical products.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Corbus Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRDF (Cardiff Oncology Corp)|BeyondSpring Pharma - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (bioatla.com)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharma (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences, Inc.|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S Aprea Therapeutics Inc. (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan